Fudan University: Cholangiocarcinoma trials
The registry lists 15 Cholangiocarcinoma studies with Fudan University as lead sponsor. 10 are open to participants now and 0 have results posted.
Phase 1 1Phase 2 12Phase 3 1No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Cryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic CholangiocarcinomaNot yet recruitingNCT07846267Phase 2
- Adjuvant Chemotherapy for BTC Based on 3D-PTANot yet recruitingNCT07296666Phase 2
- Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic CholangiocarcinomaRecruitingNCT07070700Phase 2
- Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01)RecruitingNCT06860477Phase 2
- HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICCRecruitingNCT06335927Phase 2
- Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic CholangiocarcinomaNot yet recruitingNCT06313554Not applicable
- Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free)RecruitingNCT05835245Phase 2
- Lenvatinib Plus Sintilimab in Patients with Immune Checkpoint Inhibitor Previously Treated Advanced Liver CancerRecruitingNCT05010681Phase 2
- TACE Combined with Tislelizumab in Patients with Advanced Intrahepatic CholangiocarcinomaRecruitingNCT04954781Phase 2
- Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic CholangiocarcinomaRecruitingNCT04299581Phase 2
- GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTCWithdrawnNCT05019677Phase 2
- Cryoablation Combined with Sintilimab Plus Lenvatinib in Patients with Advanced Intrahepatic CholangiocarcinomaCompletedNCT05010668Phase 2
- A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical ResectionStatus unknownNCT04856761
- Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative RecurrenceStatus unknownNCT04782804Phase 1/2
- Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic CholangiocarcinomaStatus unknownNCT02798510Phase 3